Founded Year



Loan | Alive

Total Raised


Last Raised

$250K | 2 yrs ago

About Aria Pharmaceuticals

Aria Pharmaceuticals is a preclinical-stage pharmaceutical company that discovers and develops novel small molecule therapies for complex and hard-to-treat diseases

Aria Pharmaceuticals Headquarter Location

265 Cambridge Ave #60099

Palo Alto, California, 94306,

United States


Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Research containing Aria Pharmaceuticals

Get data-driven expert analysis from the CB Insights Intelligence Unit.

CB Insights Intelligence Analysts have mentioned Aria Pharmaceuticals in 1 CB Insights research brief, most recently on Mar 16, 2022.

Expert Collections containing Aria Pharmaceuticals

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Aria Pharmaceuticals is included in 3 Expert Collections, including Artificial Intelligence.


Artificial Intelligence

9,093 items

This collection includes startups selling AI SaaS, using AI algorithms to develop their core products, and those developing hardware to support AI workloads.


Digital Health

13,075 items

Technologies, platforms, and systems that engage consumers for lifestyle, wellness, or health-related purposes; capture, store, or transmit health data; and/or support life science and clinical operations. (DiME, DTA, HealthXL, & NODE.Health)


Biopharma Tech

838 items

Latest Aria Pharmaceuticals News

Why Aria Pharmaceuticals is upbeat about two novel IPF treatment candidates

Sep 23, 2021

Drug Discovery and Development September 23, 2021 Small molecule drug developer Aria Pharmaceuticals (Palo Alto, Calif.) recently revealed that two investigational treatments for idiopathic pulmonary fibrosis (IPF), TXR-1002 and TXR-1007, demonstrated promising results in preclinical research. There are currently only two FDA-approved treatments for IPF on the market — nintedanib (Ofev) from Boehringer Ingelheim and pirfenidone (Esbriet) from Roche . While those introductions marked a turning point in treating IPF, managing the disease remains challenging for many patients. Both TXR-1002 and TXR-1007 rely on a mechanism of action than that of nintedanib or pirfenidone. And Aria reports that preclinical testing indicated that the drugs were well tolerated. “Certainly, you can’t tell if a rat is suffering from nausea or something like that, but at a gross level, the animals did well through the course of the study,” said Mark Eller, senior vice president, R&D at Aria Pharmaceuticals. “We’re optimistic based on the mechanism and the data that we’ve collected so far that we’re onto something.” Mark Eller “It’s hard to say that any given animal model is really good for something that’s idiopathic,” Eller acknowledged. But the animal model Aria used is “sort of the gold standard” and “was used for both nintedanib and pirfenidone.” The model considers both inflammation and fibrosis. TXR-1002 and TXR-1007 fared well in both respects. The company plans to conduct further testing on the two drug candidates. The preclinical research indicates that the drug candidates have significant efficacy in reducing lung collagen and the infiltration of neutrophils and lymphocytes in the lung, which are markers for inflammation. “Usually, it’s the inflammation that comes first, and then the fibrosis follows that,” Eller said. Thus, Aria’s model was focused on quantifying lung damage associated with fibrosis. In that respect, the company had “statistically significant results — in fact, numerically superior to nintedanib for lung collagen, which is a fibrosis marker.” Eller said that the reductions in neutrophils and lymphocytes were not statistically significant. “That’s probably due to the timing,” he said. Because inflammation precedes fibrosis, the company could potentially measure both variables at various times to get a clearer picture of how the investigational drugs impact both factors. The prevalence of IPF appears to have risen in recent decades, according to a 2018 paper published in  Medical Sciences . In addition, the ongoing pandemic and factors such as rampant wildfires could heighten the need for new IPF treatments. Researchers have also identified that certain occupations such as firefighting may elevate the risk for interstitial lung diseases, including IPF. “It is an important area for continued research on the part of the pharmaceutical industry,” Eller concluded.

Aria Pharmaceuticals Web Traffic

Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Aria Pharmaceuticals Rank

  • When was Aria Pharmaceuticals founded?

    Aria Pharmaceuticals was founded in 2014.

  • Where is Aria Pharmaceuticals's headquarters?

    Aria Pharmaceuticals's headquarters is located at 265 Cambridge Ave, Palo Alto.

  • What is Aria Pharmaceuticals's latest funding round?

    Aria Pharmaceuticals's latest funding round is Loan.

  • How much did Aria Pharmaceuticals raise?

    Aria Pharmaceuticals raised a total of $13.87M.

  • Who are the investors of Aria Pharmaceuticals?

    Investors of Aria Pharmaceuticals include Paycheck Protection Program, National Cancer Institute, Andreessen Horowitz, Softbank Ventures Asia, OS Fund and 4 more.

  • Who are Aria Pharmaceuticals's competitors?

    Competitors of Aria Pharmaceuticals include Insilico Medicine, BenevolentAI, Exscientia, Standigm, Recursion and 9 more.

You May Also Like

Insilico Medicine Logo
Insilico Medicine

Insilico Medicine develops a range of generative adversarial networks (GANs) and reinforcement learning approaches to identify protein targets, generate molecular structures with specified properties, and generate synthetic data. The company provides pharmaceutical and biotechnology companies with artificial intelligence solutions that transform the way innovative medicines and treatments are discovered and accelerate research and development. The company was founded in 2014 and is based in Hong Kong.

Healx Logo

Healx is an AI-powered and patient-inspired technology company, accelerating the discovery and development of rare disease treatments. Its AI drug discovery platform leverages public and proprietary biomedical data and features a knowledge graph for rare diseases.

insitro Logo

insitro is a data-driven drug discovery and development company that leverages machine learning and high-throughput biology to transform the way medicines are created to help patients.

Cyclica Logo

Cyclica is a global biotechnology company that leverages artificial intelligence and computational biophysics to reshape the drug discovery process. Cyclica's structure-based and AI-augmented drug discovery platform includes Ligand Design for multi-targeted and multi-objective drug design, and Ligand Express for off-target profiling, systems biology linkages, and structural pharmacogenomic insights.

Atomwise Logo

Atomwise uses deep learning neural networks to help discover new medicines. Atomwise achieves results for new drug hit discovery, binding affinity prediction, and toxicity detection. Atomwise predicts drug candidates for pharmaceutical companies, start-ups, and research institutions. It is currently using computational drug design to design drugs against COVID.

Standigm Logo

Standigm is an AI and systems biology-based startup that aims to expedite the drug discovery process. Standigm develops a computer modeling technology that learns medical and biological information and predicts the action mechanism of pharmaceutics in advance. This technology can improve the pharmaceutical development process by tailoring the application of previous know-hows, come up with possible combinations of pharmaceuticals, and optimize the selection of candidates and participants for clinical trials.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.